AU2003100587A4 - Granulation of Colostrum Powder - Google Patents
Granulation of Colostrum Powder Download PDFInfo
- Publication number
- AU2003100587A4 AU2003100587A4 AU2003100587A AU2003100587A AU2003100587A4 AU 2003100587 A4 AU2003100587 A4 AU 2003100587A4 AU 2003100587 A AU2003100587 A AU 2003100587A AU 2003100587 A AU2003100587 A AU 2003100587A AU 2003100587 A4 AU2003100587 A4 AU 2003100587A4
- Authority
- AU
- Australia
- Prior art keywords
- weight
- powder
- colostrum
- granulate
- colostrum powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000843 powder Substances 0.000 title claims description 49
- 210000003022 colostrum Anatomy 0.000 title claims description 41
- 235000021277 colostrum Nutrition 0.000 title claims description 41
- 238000005469 granulation Methods 0.000 title claims description 7
- 230000003179 granulation Effects 0.000 title claims description 7
- 239000008187 granular material Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 9
- 239000000600 sorbitol Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims 1
- 238000003801 milling Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 10
- 239000002245 particle Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000007910 chewable tablet Substances 0.000 description 3
- 229940068682 chewable tablet Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100035353 Cyclin-dependent kinase 2-associated protein 1 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- -1 colourings Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Description
P/00/009 Regulation 3.2
AUSTRALIA
Patents Act 1990 INNOVATION PATENT SPECIFICATION Invention Title: GRANULATION OF COLOSTRUM POWDER Applicant: GLUTAGEN PTY.LTD.
The invention is described in the following statement: C:%vnosTEMFJnnovat~on oover (l),doc 2 GRANULATION OF COLOSTRUM POWDER This invention relates to a method of treating colostrum powder to obtain a granulate which is more soluble than untreated colostrum powder.
Colostrum powder is obtained from colostrum, that is, mammalian milk produced during the first few days post-partum. It is produced by removing fats, casein, sugar and water from colostrum, to leave a powder having a high concentration of proteins. By immunising the mammal producing the colostrum against specific diseases, it is possible to obtain a colostrum powder which contains active antibodies to those diseases. It is envisaged that the colostrum powder used in the present invention may come from an immunized mammal and contain active antibodies to one or more diseases.
Production of colostrum powder from colostrum may be achieved in a number of ways, and reference is made to UK Patent 1,573,995 and to PCT Application PCT/AU94/00562, which disclose methods of obtaining colostrum powder.
High quality colostrum powder is typically 75-85% protein. The proteins may include active antibodies and other proteins, making the colostrum powder useful as a pharmaceutical or as a dietary supplement.
Although colostral proteins exist in colostrum as colloidal solutions, the high proportion of protein in colostrum powder means that it is difficult to dissolve colostrum powder in an aqueous media, such as saliva. When water or saliva contacts particles of colostrum powder, a gelatinous layer is formed on the surface of the particles, restricting water penetration to the inner core of the particles, and preventing further break-up of the particles to form a colloidal solution. This means that colostral proteins cannot readily be administered in the upper digestive tract, for example, in the form of a chewable tablet, because uptake of the colostral proteins is delayed by the poor solubility of the colostrum powder.
C:\windows\TEMP\Granulation of Colostrum Powder Innovation Patent.doc 3 The present invention seeks to provide a method by which the solubility of colostrum powder may be improved. The invention also provides a chewable tablet formulation including the treated colostrum powder.
According to the invention, colostrum powder is mixed with sorbitol. The proportion of colostrum powder to sorbitol may range from 7:3 to 3:7 by weight, but preferably the colostrum powder and sorbitol are present in substantially equal proportions by weight. The colostrum powder and sorbitol are thoroughly blended, preferably in a pharmaceutical grade blender, to form a blended powder mix. The blended powder mix is then placed in a granulating machine and an alcohol/water solution is added, preferably by spraying the solution on to the powder mix. Preferably, the alcohol is ethanol. The solution may range from 5% to 40% alcohol, but is preferably about 20% alcohol. The alcohol/water solution is added to the blended powder mix, until it reaches to 15% of the powder weight. Preferably, the alcohol/water solution is added until it reaches 10% of the powder weight. The blended powder mix and alcohol/water solution are thoroughly blended to form a uniform mass of granulate. Preferably, the addition of the alcohol/water solution and blending to form a uniform mass of granulate are carried out in a granulating machine such as a Diosna Universal Mixer/Granulator V Series, manufactured by Dierks&Sohne GmbH, Osnabruck, Germany.
After blending, the blended mass of granulate is dried, preferably on open trays at about 40 0 C. Whilst the exact temperature is not critical, care must be taken not to denature active proteins in the blended mass by over-heating. The dried granulate is then milled to a suitable size. Preferably, the granulate is milled to about size 200 mesh. The granulate produced in this way is found to be relatively soluble and suitable for use in formulating chewable, soluble colostrum tablets and other soluble pharmaceutical formulations.
The present invention also provides a chewable tablet formulation. The tablet preferably comprises 75-85%; more preferably about 80% colostrum/sorbitol granulate made in accordance with the method described above, but this proportion can be lowered, if desired, to include other active components in the C:\windows\TEMP\Granulation of Colostrumrn Powder Innovation Patent.doc 4 tablet formulation. The remainder of the tablet is comprised of fillers, binders, lubricants, flavours and sweeteners, colourings, and other pharmaceutically acceptable excipients.
Fillers which may be used in accordance with the invention include dextrose, lactose, starch, mannitol, microcrystalline cellulose, dicalcium phosphate dihydrate, calcium sulphate dihydrate, calcium carbonate, sucrose, inositol and amylose.
Binders which may be used in accordance with the invention include acacia, tragacanth, sodium alginate, guar gum, polyethylene glycol and magnesium aluminium silicate.
Lubricants which may be used in accordance with the invention include stearates, talc, waxes, sodium lauryl sulphate, magnesium lauryl sulphate, sodium acetate and silica.
Other active ingredients which may be incorporated in the tablet formulation of the invention include vitamins; minerals; gastrointestinal drugs; expectorants; microencapsulated proteins, peptides or live cells; interferon; antihistamines; antibiotics and antiemetics.
In a preferred tablet formulation in accordance with the invention, a 1200 mg tablet is produced containing the ingredients set out in Table 1.
Table 1 Component Mass (mg) Percentage by Weight Colostrum powder (Bovine) 500.00 41.67% Sorbitol 438.00 36.50% Dextrose 220.00 18.33% Magnesium Stearate 15.00 1.25% Silica-Colloidal Anhydrous 15.00 1.25% Flavouring (Vanilla) 12.00 1.00% Total 1,200.00 100.00% C:\windows\TEMP\Granulation of Colostrum Powder Innovation Patent.doc 1 Other formulations using different excipients or including further active ingredients are envisaged, and fall within the scope of the present invention.
C:%witndows\TEMP\Granulaio of Colostrum Powder Innovation Patent.doc
Claims (4)
1. A method of treating colostrum powder to obtain a granulate which is more soluble than untreated colostrum powder, comprising the steps of: a) mixing colostrum powder with sorbitol in a weight ratio of from 3:7 to 7:3 to produce a blended powder mix; b) adding the blended powder mix to a granulator, together with sufficient solution of from 5 to 40% alcohol in water to reach 5 to of the weight of the blended powder mix, and blending to form a uniform mass of granulate; c) drying the granulate at a temperature low enough to avoid denaturing proteins in the colostrum powder; and d) milling the dried granulate.
2. A method according to claim 1 wherein the weight ratio of colostrum powder to sorbitol is about 1:1; the solution of alcohol in water added to the blended powder mix is a 20% solution of ethanol in water, which is added to the blended powder mix by spraying until the weight of the solution is about 10% of the weight of the blended powder mix; and wherein the granulate is dried on an open tray at a temperature of about 400C, and then milled to size 200 mesh.
3. A tablet containing a granulate produced in accordance with either one of claims 1 or 2.
4. A tablet in accordance with claim 3, wherein the granulate forms about percent by weight of the tablet. C:\wndows\TEMP\GranulaUtion of Colostrum Powder Innovation Patent.doc A tablet in accordance with either one of claims 3 or 4, comprising 41.67 weight colostrum powder, 36% weight sorbitol, 18.33 weight dextrose, 1.25 weight magnesium stearate, 1.25 weight silica- colloidal anhydrous and 1 weight flavouring. DATED 17 July, 2003 PHILLIPS ORMONDE FITZPATRICK Attorneys for: GLUTAGEN PTY LTD C:\windows\TEMP\Granulation of Colostrum Powder Innovation Patent.doc
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003100587A AU2003100587A4 (en) | 2003-07-17 | 2003-07-17 | Granulation of Colostrum Powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003100587A AU2003100587A4 (en) | 2003-07-17 | 2003-07-17 | Granulation of Colostrum Powder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003100587A4 true AU2003100587A4 (en) | 2003-10-09 |
Family
ID=34069734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003100587A Ceased AU2003100587A4 (en) | 2003-07-17 | 2003-07-17 | Granulation of Colostrum Powder |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2003100587A4 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024189541A1 (en) | 2023-03-13 | 2024-09-19 | University Of Tartu | Colostrum tablets |
-
2003
- 2003-07-17 AU AU2003100587A patent/AU2003100587A4/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024189541A1 (en) | 2023-03-13 | 2024-09-19 | University Of Tartu | Colostrum tablets |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2854839B1 (en) | Methods of treating celiac disease | |
| EP3154529B1 (en) | Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use | |
| AU2002238848B2 (en) | Use of a spray-dried powder comprising a sugar alcohol | |
| CZ20002391A3 (en) | Flash-melt oral dosage formulation and process for preparing thereof | |
| CN1326338A (en) | Process for preparing oral calcium compositions | |
| JPWO1996025158A1 (en) | Pharmaceutical composition containing azulene derivative and method for producing the same | |
| JPH07149648A (en) | Sustained release unit dosage form and method for producing the same | |
| JPH05221854A (en) | Controlling release tablet containing watersoluble chemical | |
| HU229892B1 (en) | Fast-dispersing dosage forms containing fish gelatin | |
| IE60069B1 (en) | Controlled release dihydrocodeine composition | |
| EP0748628A2 (en) | Oral formulations of S(+)-Etodolac | |
| WO2018158459A1 (en) | Orodispersible tablet containing burlulipase and pharmaceutical composition produced therefrom | |
| KR101631846B1 (en) | Solid preparations containing choline alfoscerate and preparing method thereof | |
| US4670251A (en) | Microcrystalline tableting excipient derived from whey | |
| PH12015500467B1 (en) | Method for producing extended-release potassium citrate wax matrix tablet | |
| AU2003100587A4 (en) | Granulation of Colostrum Powder | |
| JP2010254580A (en) | Method for producing arginine-containing tablets | |
| JP2018184364A (en) | Tablet and method for producing the same | |
| EP0759300B1 (en) | process for producing molten granulated sucralfate preparations | |
| JP2010270111A (en) | Arginine-containing tablet | |
| JP6891113B2 (en) | Tablets high in arginine | |
| JPH0656677A (en) | Antacid composition | |
| JP2000191517A (en) | Granulated composition with unpleasant taste masked and method for producing the same | |
| JP2000044463A (en) | Rapidly dissolvable tablet | |
| JP2003250488A (en) | Food composition and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGI | Letters patent sealed or granted (innovation patent) | ||
| MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |